Virax Biolabs Group Limited VRAX
2.40
(0.04)
(1.64%)
as of 25 Sep
- Market cap
- $3.3M
- P/E
- 0.0×
Follow VRAX
| Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | — | 1.23 | 0.46 | 0.56 | 0.86 |
EV/Operating CF |
0.00 | 0.00 | — | 1.22 | 0.21 | 0.26 | 0.46 |
EV/FCF |
0.00 | 0.00 | — | 1.22 | 0.20 | 0.23 | 0.42 |
Quick Ratio |
0.02 | 0.02 | 0.02 | 10.30 | 22.55 | 6.33 | 9.44 |
Current Ratio |
0.05 | 0.05 | 0.04 | 10.61 | 25.95 | 7.27 | 9.97 |
Net Debt/EBITDA |
(1.41) | (0.25) | 0.01 | 1.61 | 0.56 | 0.73 | 1.08 |
Debt/Assets |
1,917.68% | 453.28% | 7.80% | 1.49% | 0.00% | 0.51% | 0.34% |
Debt/Equity |
(0.91) | (0.22) | 0.00 | 0.02 | 0.00 | 0.01 | 0.00 |
Asset Turnover |
0.00 | 3.13 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
1.14 | 0.91 | 0.48 | 0.77 | 0.93 | 0.75 | 0.92 |
Capex/Depreciation |
— | — | — | 0.00 | (11.29) | (1.76) | (0.58) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 23.85% | 168.48% | (141.62%) | (95.90%) | (114.35%) | (78.51%) | |
| 0.00% | (1,643.94%) | (3,870.44%) | (110.69%) | (88.04%) | (101.78%) | (68.11%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (262.02%) | (300.05%) | (432.65%) |
Return on Tangible Assets |
78.26% | 78.26% | 142.79% | (62.55%) | (131.79%) | (111.27%) | (68.70%) |
Average Days of Receivables |
2.65 | 2.65 | — | 0.00 | 508.29 | 1,778.65 | 797.70 |
Research and Development Expense of Revenue |
70.27% | 97.09% | 0.00% | 25,340.70% | 998.72% | 32,242.86% | 30,148.39% |
Selling, General and Administrative Expense of Revenue |
415.91% | 415.91% | 0.00% | 41,303.49% | 2,937.79% | 63,371.43% | 21,525.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 20,402.33% | 647.06% | 5,798.41% | 1,051.61% |
Graham Net Nets |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(0.38%) | (0.38%) | — | (3.07%) | (29.00%) | (18.70%) | (96.91%) |
Free Cash Flow Yield |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.11 | 12.90 | 0.00 | 0.20 | 1.95 | 0.04 | 0.03 |
Operating CF per Share |
(0.65) | (61.48) | (21.20) | (98.35) | (77.89) | (30.59) | (11.62) |
Capex per Share |
0.00 | 0.00 | 0.00 | (4.20) | (14.52) | (4.05) | (0.64) |
Free Cash Flow per Share |
(0.65) | (61.48) | (21.20) | (102.55) | (92.41) | (34.63) | (12.27) |
Cash per Share |
0.02 | 1.83 | 0.57 | 220.06 | 44.75 | 28.34 | 16.19 |
Shareholders Equity per Share |
(0.73) | (86.65) | (31.25) | 209.51 | 64.07 | 36.61 | 18.45 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.73) | (86.65) | (31.25) | 209.51 | 64.07 | 36.61 | 18.45 |
Free Cash Flow |
(0.74) | (0.59) | (0.81) | (4.36) | (7.41) | (5.17) | (4.88) |
Working Capital |
(0.83) | (0.83) | (1.20) | 8.73 | 4.21 | 4.22 | 6.14 |
Capital Expenditures |
— | — | — | (0.18) | (1.16) | (0.60) | (0.26) |
Net Current Asset Value |
(0.83) | (0.83) | (1.20) | 8.73 | 4.04 | 3.93 | 5.84 |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | — | 20.74 | 7.45 | 95.86 | 20.63 |
Net Profit Margin |
(525.85%) | (525.85%) | 0.00% | (63,459.30%) | (4,305.31%) | (96,209.52%) | (40,514.52%) |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | — | — | — | 0.11 | 0.28 | 0.38 |
Cash ROIC |
1,358.76% | 92.99% | 69.34% | (22.71%) | (81.86%) | (59.55%) | (41.95%) |
Accounts Receivable Turnover |
0.00 | 137.56 | — | 0.00 | 1.43 | 0.05 | 0.43 |
Accounts Payable Turnover |
0.00 | 0.38 | 0.00 | 0.01 | 0.25 | 0.17 | 0.01 |
Inventory Turnover |
0.00 | 6.32 | 0.00 | 0.00 | 2.60 | 0.77 | 0.10 |
Average Days of Payables |
582.69 | 1,359.78 | 0.00 | 26,689.24 | 417.09 | 3,611.29 | 44,685.32 |
Days of Inventory on Hand |
57.78 | 57.78 | 0.00 | 0.00 | 208.37 | 581.91 | 0.00 |
Average Receivables |
— | 0.00 | — | — | 0.11 | 0.12 | 0.03 |
Average Payables |
— | 0.35 | 0.87 | 0.98 | 0.42 | 0.35 | 0.58 |
Average Inventory |
— | 0.02 | 0.02 | — | 0.04 | 0.08 | 0.05 |
Average Assets |
— | 0.04 | 0.04 | 4.93 | 7.65 | 5.96 | 7.38 |
Average Common Equity |
— | (2.73) | (1.01) | 3.85 | 7.02 | 5.30 | 6.40 |
Columns are period end dates